多发结直肠息肉患者中息肉病及结直肠癌相关基因胚系突变患病率研究
这项横断面研究纳入2012年3月至2016年12月接受多基因面板检测的3789例≥10枚结直肠息肉患者,按年龄分层分析胚系突变患病率。腺瘤性息肉病基因突变率随年龄增长而下降(P<.001),但所有年龄及息肉计数队列中任一目标基因突变率均高于5%;错构瘤队列中错构瘤性息肉病基因突变率在10-19枚息肉者为40%、20-99枚者为72.1%、≥100枚者为50%。作者认为结果支持对≥10枚息肉患者继续开展基因检测。
要点
- ≥10枚结直肠息肉患者中,腺瘤性息肉病基因突变率随年龄增长而下降(P<.001)。
- 所有年龄和息肉计数队列中,任一目标基因突变率均保持在5%以上。
- 错构瘤队列中错构瘤性息肉病基因突变率较高(10-19枚40%、20-99枚72.1%、≥100枚50%)。
核心结论
- 研究结果支持对≥10枚息肉(包括腺瘤和/或错构瘤)的患者继续开展基因检测。
- 鉴于所有年龄组中突变比例均高于5%,作者认为对这些患者应考虑包含息肉病及非息肉病结直肠癌基因分析的多基因面板检测。
研究设计与样本
- 横断面研究,纳入2012年3月至2016年12月接受多基因面板检测的≥10枚结直肠息肉患者,共3789例。
- 人口学、临床及家族史数据来自检测申请单及随附的临床记录、系谱和病理报告。
- 受试者根据报告的息肉组织学进行分层。
主要发现
- 在腺瘤队列中,所有息肉计数分组(10-19枚、20-99枚、≥100枚)的腺瘤性息肉病基因突变患病率均随年龄增长而下降(P<.001)。
- 所有目标基因的突变患病率也随年龄增长而下降,但在所有年龄和息肉队列中均保持在5%以上。
- 多因素分析显示,检测时年龄增大与任一目标基因突变风险显著降低相关。
- 在错构瘤队列中,错构瘤性息肉病基因突变患病率与息肉计数无关且较高:10-19枚者为40%,20-99枚者为72.1%,≥100枚者为50%。
临床怎么用
- 作者认为,对≥10枚息肉(包括腺瘤和/或错构瘤)的患者应考虑包含息肉病及非息肉病结直肠癌基因分析的多基因面板检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Guidelines recommend genetic testing of patients with 10 or more cumulative adenomatous polyps. However, little is known about the utility of these tests-especially for older patients. We aimed to determine the prevalence of pathogenic mutations in patients with multiple colorectal polyps, stratified by age. METHODS: We performed a cross-sectional study of patients with 10 or more colorectal polyps who underwent multigene panel testing (MGPT) from March 2012 through December 2016 (n = 3789). Demographic, clinical and family history data were obtained from test requisition forms and accompanying clinic notes, pedigrees, and pathology reports. Subjects were stratified based on reported polyp histology. Primary outcomes of interest were gene mutations associated with adenomatous polyposis, hamartomatous polyposis, and non-polyposis colorectal cancer syndromes. RESULTS: Based on MGPT, the prevalence of mutations in adenomatous polyposis genes decreased with increasing age in all polyp count groups in the adenoma cohort (P < .001 for 10-19, 20-99, and 100 or more polyps). The prevalence of mutations in all genes of interest also decreased with increasing age but remained above 5% in all age and polyp cohorts. Increased age at testing was associated with a significantly lower risk of a mutation in any gene of interest with multivariate analysis. In the hamartoma cohort, the prevalence of mutations in hamartomatous polyposis genes was high regardless of polyp count (40% with 10-19 polyps, 72.1% with 20-99 polyps, and 50% with 100 or more polyps). CONCLUSION: Our findings support continued genetic testing of patients with 10 or more polyps including adenomas and/or hamartomas. MGPT that includes analysis of polyposis and non-polyposis colorectal cancer genes should be considered for these patients given the high proportion with mutations (above 5%) in all age groups.
引用
- Stanich PP, Pearlman R, Hinton A, et al. Prevalence of Germline Mutations in Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colorectal Polyps. Clin Gastroenterol Hepatol. 2018. PMID: 30557735. doi:10.1016/j.cgh.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。